SCHEMBL10043933

SCHEMBL10043933

Cc1cc2c(cn1)cc(-c1cc(C(=O)NC(=O)Nc3ccc(Cl)cn3)ccc1C)c(=O)n2C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.46
NPC1 O15118 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.43
TP53 P04637 3/20 0.43
TSHR P16473 2/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
MAPK1 P28482 2/20 0.42
KMT2A Q03164 3/20 0.41
POLB P06746 1/20 0.41
PKM P14618 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
FGFR1 P11362 2/20 0.39
SRC P12931 2/20 0.39
MAPK14 Q16539 6/20 0.39
CYP2C19 P33261 2/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043907 0.93 RAB9A (0.51) RAB9ANPC1SMN1; SMN2TP53TSHR
SCHEMBL10043944 0.91 SRC (0.41) RAB9ANPC1SMN1; SMN2TSHRL3MBTL1
SCHEMBL10043942 0.90 PCTP (0.44) RAB9ANPC1KMT2AALDH1A1FGFR1
SCHEMBL10043928 0.87 RAB9A (0.45) RAB9ANPC1SMN1; SMN2TP53KMT2A
SCHEMBL10043851 0.86 PCTP (0.44) RAB9ANPC1SMN1; SMN2TP53POLB
SCHEMBL10043946 0.85 ALDH1A1 (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1MAPK14
SCHEMBL10043936 0.85 NPC1 (0.48) RAB9ANPC1SMN1; SMN2TP53MAPK1
SCHEMBL10043948 0.85 MAPK14 (0.42) RAB9ANPC1POLBFGFR1SRC
SCHEMBL10043938 0.84 MAPK14 (0.55) RAB9AKMT2APOLBALDH1A1MAPK14
SCHEMBL501911 0.84 SYK (0.46) RAB9ANPC1KMT2AFGFR1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885NPC1 4095/4885SMN1; SMN2 2302/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885NPC1 4095/4885SMN1; SMN2 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.